News for Catalent, Inc. (CTLT)

PR NewswireAUSTIN, Texas, June 4, 2025 New vendor-agnostic interoperability advancements in Oracle Randomization and Trial Supply Management enable drug po

PR NewswireATLANTA, May 22, 2025 ATLANTA, May 22, 2025 /PRNewswire/ -- Graphic Packaging Holding Company (NYSE: GPK), a global leader in sustainable consum

Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that four new directors will join its Board of Directors and that four long-time mem

Exploring Caxton Associates (Trades, Portfolio)' Recent 13F Filing Caxton Associates (Trades, Portfolio) recently submitted its 13F filing for the fourth quart

Beleaguered shareholders of BP Plc who’ve watched their investment lag over the past few years are banking on activist Elliott Investment Management LP’s track reco…

Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. ( JUNS) (”œJupiter” or the ”œCompany”), a clinical-stage pharmaceutical

Novo Nordisk's valuation now more attractive: Bernstein

GLP-1: Barclays on why 2025 could be an inflection point

BILL stock rises on S&P MidCap 400 inclusion

Lennox International to join S&P 500, shares rise

Novo Holdings completes $16.5 billion acquisition of Catalent Inc, with Novo Nordisk A/S acquiring Catalent's fill-finish sites in Italy, USA, and Belgium.

Novo Nordisk stock rises following regulatory clearance of Catalent deal

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Catalent, Inc. (CTLT) and Novo Holdings A/S have jointly announced that they have successfully met all regulatory closing conditions for their pending transac

Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say

Catalent, Inc. (”œCatalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S

Earnings call: Thermo Fisher raises EPS guidance amid steady growth

Exclusive-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show